Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M Kündig

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
Immunology and Allergy Clinics of North America|December 1, 2015
Novel Delivery Routes for Allergy Immunotherapy: Intralymphatic, Epicutaneous, and IntradermalGabriela Senti, Thomas M Kündig
Journal of Visualized Experiments : Jove|February 12, 2014
Intralymphatic immunotherapy and vaccination in micePål Johansen, Thomas M Kündig
The World Allergy Organization Journal|March 18, 2015
Intralymphatic immunotherapyGabriela Senti, Thomas M Kündig
Human Vaccines|June 5, 2010
Allergen-specific immunotherapy: regulatory T cells or allergen-specific IgG?Thomas M Kündig, Martin F Bachmann
Current Opinion in Allergy and Clinical Immunology|August 15, 2009
Intralymphatic immunotherapyGabriela Senti, Pål Johansen, Thomas M Kündig
Therapeutische Umschau. Revue Therapeutique|March 26, 2010
[Urticaria - the most frequent dermatological disease]Barbara K Ballmer-Weber, Thomas M Kündig
Current Topics in Microbiology and Immunology|July 5, 2011
Intralymphatic immunotherapy: from the rationale to human applicationsGabriela Senti, Pål Johansen, Thomas M Kündig
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 26, 2021
Epitranscriptomics modifier pentostatin indirectly triggers Toll-like receptor 3 and can enhance immune infiltration in tumorsMarina Tusup, Thomas M Kündig, Steve Pascolo
Allergy|April 27, 2011
Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy?G Senti, S von Moos, Thomas M Kündig
Current Opinion in Allergy and Clinical Immunology|August 15, 2009
Modular antigen-translocation as a novel vaccine strategy for allergen-specific immunotherapyReto Crameri, Thomas M Kündig, Cezmi A Akdis
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
Immunology and Allergy Clinics of North America|December 1, 2015
Novel Delivery Routes for Allergy Immunotherapy: Intralymphatic, Epicutaneous, and IntradermalGabriela Senti, Thomas M Kündig
Journal of Visualized Experiments : Jove|February 12, 2014
Intralymphatic immunotherapy and vaccination in micePål Johansen, Thomas M Kündig
The World Allergy Organization Journal|March 18, 2015
Intralymphatic immunotherapyGabriela Senti, Thomas M Kündig
Human Vaccines|June 5, 2010
Allergen-specific immunotherapy: regulatory T cells or allergen-specific IgG?Thomas M Kündig, Martin F Bachmann
Current Opinion in Allergy and Clinical Immunology|August 15, 2009
Intralymphatic immunotherapyGabriela Senti, Pål Johansen, Thomas M Kündig
Therapeutische Umschau. Revue Therapeutique|March 26, 2010
[Urticaria - the most frequent dermatological disease]Barbara K Ballmer-Weber, Thomas M Kündig
Current Topics in Microbiology and Immunology|July 5, 2011
Intralymphatic immunotherapy: from the rationale to human applicationsGabriela Senti, Pål Johansen, Thomas M Kündig
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 26, 2021
Epitranscriptomics modifier pentostatin indirectly triggers Toll-like receptor 3 and can enhance immune infiltration in tumorsMarina Tusup, Thomas M Kündig, Steve Pascolo
Allergy|April 27, 2011
Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy?G Senti, S von Moos, Thomas M Kündig
Current Opinion in Allergy and Clinical Immunology|August 15, 2009
Modular antigen-translocation as a novel vaccine strategy for allergen-specific immunotherapyReto Crameri, Thomas M Kündig, Cezmi A Akdis
Pageof 13